Mitoxantrone Quantification by HPLC-MS/MS in Caco-2 Culture Media

Mitoxantrone is a marker substrate of breast cancer resistance protein (BCRP). BCRP is involved in a number of pharmacokinetic drug-drug interactions. The transporter’s possible saturability makes it advisable to use low concentrations of mitoxantrone for in vitro studies. Consequently, mitoxantrone quantification requires   a method with high sensitivity.

The aim of the study was to develop and validate a procedure for mitoxantrone quantification in Caco-2 culture media by HPLC-MS/MS.

Materials and methods.  The  authors  used  an  Ultimate  3000  HPLC  system  and a TSQ Fortis triple quadrupole mass spectrometer by Thermo Fisher Scientific and a Selectra C18 column (4.6×100 mm, 5 μm, 100 Å) by United Chemical Technologies. The elution ran in a gradient mode with a mobile phase of 1% formic acid solution and methanol. Experimental parameters were as follows: eluent flow rate, 0.3 mL/min; separation column temperature, 35 °C; injection volume, 5  μL; ana lysis time, 10 min; approximate mitoxantrone retention time, 5.51 min. The sample preparation involved protein precipitation from the culture medium with methanol, followed by centrifugation at 13,000 g for 10 min. The detection was performed using electrospray ionisation in the positive ion mode. Detection parameters were   as follows: electrospray voltage, 3700 V; sheath gas flow rate, 50 L/min; auxiliary    gas flow rate, 10 L/min; sweep gas flow rate, 1 L/min; ion-transfer tube temperature, 300 °C; and evaporator temperature, 350 °C. The detection was set at mass transitions of m/z 455 to 88.2 and m/z 455 to 358.1, with the collision energy for these transitions amounting to 25 V and 18 V, respectively. The source fragmentation was at 0, and the CID gas pressure was at 2 mTorr.

Results. The analytical procedure showed selectivity, high sensitivity (limit of detection, 10 nmol/L; lower limit of quantification, 50 nmol/L), accuracy, precision, and linearity in the concentration range of 50–1000 nmol/L. The authors observed no carryover or matrix effects. A simulation of real-life storage conditions demonstrated high stability of mitoxantrone samples. Thus, the analytical procedure enables preclinical evaluation of medicinal product effects on the functional activity of BCRP, based on assessing the transcellular mitoxantrone transport in the presence of a test product.

Conclusion. The authors developed and validated the analytical procedure for mitoxantrone quantification in Caco-2 culture media by HPLC-MS/MS.

1. Martinelli Boneschi F, Vacchi L, Rovaris M, Capra R, Comi G. Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev. 2013;31(5):CD002127. https://doi.org/10.1002/14651858.CD002127.pub3

2. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA. 1998;95(26):15665–70. https://doi.org/10.1073/pnas.95.26.15665

3. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 2001;61(8):3458–64. PMID: 11309308

4. Mao Q, Unadkat JD. Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport — an update. AAPS J. 2015;17(1):65–82. https://doi.org/10.1208/s12248-014-9668-6

5. Kawahara I, Nishikawa S, Yamamoto A, Kono Y, Fujita T. The impact of breast cancer resistance protein (BCRP/ABCG2) on drug transport across Caco-2 cell monolayers. Drug Metab Dispos. 2020;48(6):491–8. https://doi.org/10.1124/dmd.119.088674

6. Erokhina PD, Abalenikhina YuV, Shchulkin AV, Chernykh IV, Popova NM, Slepnev AA, Yakusheva EN. A study of influence of progesterone on activity of Glycoprotein-P in vitro. I.P. Pavlov Russian Medical Biological Herald. 2020;28(2):135–42 (In Russ.). https://doi.org/10.23888/PAVLOVJ2020282135-142

7. Erokhina PD, Abalenikhina YuV, Shchulkin AV, Chernykh IV, Kotlyarova AA, Pravkin SK, et al. Study of influence of estradiol on the activity of P-glycoprotein in vitro. Science of the Young (Eruditio Juvenium). 2020;8(3):329–36 (In Russ.). https://doi.org/10.23888/HMJ202083329-336

8. Zhang P, Ling G, Sun J, Sun Y, Pu X, Wang Z, He Z. Determination of mitoxantrone in rat plasma by liquid chromatography-tandem mass spectrometry method: Application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878(24):2260–5. https://doi.org/10.1016/j.jchromb.2010.06.016

9. Mylnikov PYu, Tranova YuS, Shchulkin AV, Yakusheva EN. Development and validation of the method for the quantitative determination of methotrexate in a transport medium by HPLC-MS/MS. Pharmacokinetics and Pharmacodynamics. 2021;(1):45–51 (In Russ.). https://doi.org/10.37489/2587-7836-2021-1-45-51

10. Hsieh Y. HPLC-MS/MS in drug metabolism and pharmacokinetic screening. Expert Opin Drug Metab Toxicol. 2008;4(1):93–101. https://doi.org/10.1517/17425255.4.1.93

11. Tietze R, Schreiber E, Lyer S, Alexiou C. Mitoxantrone loaded superparamagnetic nanoparticles for drug targeting: a versatile and sensitive method for quantification of drug enrichment in rabbit tissues using HPLC-UV. J Biomed Biotechnol. 2010;2010:597304. https://doi.org/10.1155/2010/597304

12. Gameiro M, Silva R, Rocha-Pereira C, Carmo H, Carvalho F, Bastos ML, Remião F. Cellular models and in vitro assays for the screening of modulators of P-gp, MRP1 and BCRP. Molecules. 2017;22(4):600. https://doi.org/10.3390/molecules22040600